North & North · Peptide Catalog
Tirzepatide
Dual GIP and Incretin Receptor Agonist
Most peptides in this space work one receptor. This one works two at once, and that single design decision is what made the whole field pay attention.
The short version
What Tirzepatide actually is
Your gut releases hormones after you eat that tell the pancreas to release insulin, and tell the brain you have had enough. Tirzepatide is a synthetic 39 amino acid peptide built to act on two of those hormone receptors at the same time rather than one. It is the compound that made dual agonism the obvious next question, and the reason a third receptor was tried after it.
Sold for research purposes only.
The mechanism
How Tirzepatide Works
One receptor was the whole field. Then somebody asked what happens if you pull two levers at once.
Tirzepatide is built to bind two receptors at once, GIP and the incretin receptor, rather than the single target most earlier compounds in this class were designed around. Both sit in the pathway your body already uses to respond to a meal. GIP is the one that had been largely set aside, and putting it back in alongside the other is the whole design idea. A fatty acid chain attached to the peptide is what slows how quickly it clears, which is the property that made long duration study designs practical in the first place.
Where the science stands
Key Research Areas
- 01
Weight management
This is where the search volume is and where the trials are. The published work looks at body weight over long study periods, and it is the reason most people arrive at this page in the first place.
- 02
Blood sugar and insulin
It started here, in type 2 diabetes research, before weight became the headline. The two are the same underlying question asked from different ends: how the body handles fuel after a meal.
- 03
Appetite signaling
The receptors it acts on sit in the gut and the brain both. That is the proposed reason appetite shows up in the literature alongside the metabolic markers, rather than as a separate topic.
- 04
Cardiovascular markers
Cholesterol fractions and blood pressure are reported alongside the weight numbers in the large trials, so this compound turns up in cardiovascular literature as well as metabolic literature.
- 05
Why two receptors
The interesting part for researchers is not that it works, it is the combination. GIP and the incretin pathway do different jobs, and studying them together is a different question from studying either alone.
The evidence
What the Research Actually Did
The trial that made this compound the reference point in its class. Adults with obesity, 72 weeks, placebo controlled, and the readout that everything afterward gets compared against.
Jastreboff et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med, July 2022. SURMOUNT-1.The head to head. Rather than testing against placebo, this put tirzepatide directly against the leading single receptor compound in adults with obesity, which is the comparison the field actually wanted.
Aronne et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med, July 2025. SURMOUNT-5.The regulatory record itself, for the finished prescription product rather than for research material. It is the primary source behind the distinction this page draws between the two.
U.S. Food and Drug Administration. Approval announcement for chronic weight management.
We pulled this together from published work and linked every source, so you never have to take our word for it. Nothing here is a claim about what these compounds do. We would rather you read the sources than trust the summary.
Quality and supply
Tirzepatide Specifications
- Product contents
- Tirzepatide lyophilized powder in 3mL vial
- Available sizes
- 10mg · 30mg
- Peptide type
- Dual GIP and Incretin Receptor Agonist. 39 amino acids, fatty acid modified
- Purity
- >99% Purity · HPLC
- Storage
- Store at 6°C or below, sealed, away from heat, light, and moisture
- Solubility
- Soluble in water
- Fulfillment
- USA domestic fulfillment
- Molecular formula
- C225H348N48O68
- Molecular weight
- 4813.53 g/mol
- CAS number
- 2023788-19-2
- Synonyms
- LY3298176, LY-3298176
- Appearance
- White to off white lyophilized powder
Common questions
Questions People Ask
What is Tirzepatide?
A synthetic 39 amino acid peptide designed to act on two gut hormone receptors at once, GIP and the incretin receptor, rather than one. Research centers on metabolic markers, body weight and appetite signaling. Sold for research purposes only.
How is it different from Retatrutide?
Tirzepatide acts on two receptors. Retatrutide adds a third. They are the same idea taken one step further, which is exactly why they get compared so often.
What does dual agonist mean?
An agonist is something that switches a receptor on. A dual agonist switches on two different ones. Most earlier compounds in this class were built around a single receptor, so acting on two was the departure.
Is this the same as the prescription medication?
No. Tirzepatide is the active ingredient in prescription medications approved by the FDA for chronic weight management. North & North offers Tirzepatide as a separate research product, not the approved finished drug product.
What sizes does North & North supply?
Tirzepatide is available in 10mg and 30mg vials, as lyophilized powder, at >99% purity by HPLC.
How should it be stored?
Sealed, at 6°C or below, away from heat, light and moisture. It ships as a lyophilized powder, which is the stable form.
Catalog access
Create a Free Account
Create a quick and easy free account to shop Tirzepatide and other peptides.
Free to create. You will verify your email address before the catalog opens.